Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Precigen stock

Own Precigen stock in just a few minutes.

Precigen, Inc is a biotechnology business based in the US. Precigen shares (PGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Precigen employs 423 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Precigen

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PGEN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Precigen share price

Use our graph to track the performance of PGEN stocks over time.

Precigen shares at a glance

Information last updated 2021-04-23.
52-week range$2.15 - $11.10
50-day moving average $7.85
200-day moving average $7.49
Wall St. target price$12.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.09

Buy Precigen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Precigen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Precigen financials

Revenue TTM $103.2 million
Gross profit TTM $6 million
Return on assets TTM -14%
Return on equity TTM -149.44%
Profit margin -165.27%
Book value N/A
Market capitalisation $1.6 billion

TTM: trailing 12 months

Shorting Precigen shares

There are currently 27.0 million Precigen shares held short by investors – that's known as Precigen's "short interest". This figure is 15.6% up from 23.3 million last month.

There are a few different ways that this level of interest in shorting Precigen shares can be evaluated.

Precigen's "short interest ratio" (SIR)

Precigen's "short interest ratio" (SIR) is the quantity of Precigen shares currently shorted divided by the average quantity of Precigen shares traded daily (recently around 1.6 million). Precigen's SIR currently stands at 16.68. In other words for every 100,000 Precigen shares traded daily on the market, roughly 16680 shares are currently held short.

However Precigen's short interest can also be evaluated against the total number of Precigen shares, or, against the total number of tradable Precigen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Precigen's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Precigen shares in existence, roughly 130 shares are currently held short) or 0.2679% of the tradable shares (for every 100,000 tradable Precigen shares, roughly 268 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Precigen.

Find out more about how you can short Precigen stock.

Precigen share dividends

We're not expecting Precigen to pay a dividend over the next 12 months.

Precigen share price volatility

Over the last 12 months, Precigen's shares have ranged in value from as little as $2.15 up to $11.1. A popular way to gauge a stock's volatility is its "beta".

PGEN.US volatility(beta: 2.35)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Precigen's is 2.3464. This would suggest that Precigen's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Precigen overview

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site